TY - JOUR T1 - Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00049-2018 VL - 4 IS - 4 SP - 00049-2018 AU - Sophie V. Fletcher AU - Mark G. Jones AU - Elizabeth A. Renzoni AU - Helen Parfrey AU - Rachel K. Hoyles AU - Katherine Spinks AU - Maria Kokosi AU - Apollinaris Kwok AU - Chris Warburton AU - Vanessa Titmuss AU - Muhunthan Thillai AU - Nicola Simler AU - Toby M. Maher AU - Christopher J. Brereton AU - Felix Chua AU - Athol U. Wells AU - Luca Richeldi AU - Lisa G. Spencer Y1 - 2018/10/01 UR - http://openres.ersjournals.com/content/4/4/00049-2018.abstract N2 - Nintedanib, a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF), reduces annual forced vital capacity (FVC) decline in these patients by ∼50% with combined analysis of data from clinical trials showing a trend towards reduction in mortality [1–3]. Nintedanib prescription criteria for the treatment of IPF vary between countries and in 2016, the National Institute for Health and Care Excellence approved nintedanib in England and Wales for patients with an FVC between 50% and 80% predicted [4]. Prior to this approval, nintedanib was available through a manufacturer-funded programme with varying prescribing criteria. We investigated the safety and tolerability of nintedanib in UK clinical practice during this period in which FVC prescription criteria differed from those now available in routine practice.In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67 ER -